戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 st Cancer Research Fund, AstraZeneca, Sanofi Aventis.
2 gie Digestive (FFCD), Merck KGaA, and Sanofi-Aventis.
3 Ligue Nationale Contre le Cancer, and Sanofi-Aventis.
4           UK National Health Service, Sanofi-Aventis.
5   Stanley Medical Research Institute; Sanofi-Aventis.
6 on, Taiho, Hengrui Pharmaceutical and Sanofi-Aventis.
7         National Cancer Institute and Sanofi-Aventis.
8 Ligue Nationale Contre le Cancer, and Sanofi-Aventis.
9     Antimony therapy with Glucantime (Sanofi-Aventis; 20 mg/kg/day) was administered for 20 days.
10            National Cancer Institute, Sanofi-Aventis, and Abbott Laboratories.
11 a, Breast Cancer Research Foundation, Sanofi Aventis, and AstraZeneca.
12 d Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.
13 cil Australia (GNT300755, GNT569213), Sanofi-Aventis, and AstraZeneca.
14 ty Clinical Scientist Program, Taiho, Sanofi-Aventis, and Hengrui Pharmaceutical.
15 C, the National Cancer Institute, Eli Lilly, Aventis, and the University of Michigan.
16  (YF-vax [Connaught Laboratories], Stamaril [Aventis], and YF-FIOCRUZ [FIOCRUZ-Bio-Manguinhos]).
17 alth and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKl
18 ing by hydroxychloroquine (Plaquenil; Sanofi-Aventis, Bridgewater, NJ), a drug commonly prescribed to
19 ion of Ontario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germa
20                                       Sanofi Aventis (grant to the University of Leicester).
21                 [New York, New York], sanofi-aventis Group [Paris, France], and Nektar Therapeutics [
22  Institute, US Department of Defense, Sanofi-Aventis, Gynecologic Cancer Foundation, Marcus Foundatio
23 c drugs, such as clopidogrel (Plavix; sanofi-aventis); however, very little is known about the ADP-pr
24 Cancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Council (London, UK).
25     Recent primary vaccine trials of diluted Aventis Pasteur smallpox vaccine (APSV) demonstrated tha
26 e and 1 week after primary immunization with Aventis Pasteur smallpox vaccine.
27 were vaccinated with a 1 : 5 dilution of the Aventis Pasteur smallpox vaccine.
28             A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120
29 ent clinical trials of the smallpox vaccine (Aventis Pasteur) were conducted in healthy, vaccinia vir
30 , Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Resear
31 theter and subcutaneous enoxaparin (Lovenox, Aventis Pharmaceuticals, Parsippany, NJ) were administer